Drug news
FDA approves Duavee (Pfizer) for Menopause
Pfizer Inc has. announced that the FDA has approved Duavee (conjugated oestrogens/bazedoxifene) 0.45mg / 20mg tablets, a novel therapy for women with a uterus, for the treatment of moderate-to-severe vasomotor symptoms associated with Menopause and the prevention of Post Menopausal Osteoporosis. This is the first approval of Duavee in any country worldwide.
.Pfizer anticipates that Duavee will be available in the U.S. in the first quarter of 2014.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins